Tempus AI Aktie News

Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry acquisition, though organic growth in oncology and data licensing remains robust. The precision medicine company landed another $150 million in data licensing contracts.

Cathie Wood added to her stakes in Circle Internet Group, Bitmine Immersion, and Tempus AI on Thursday. The three stocks fell as much as 10% on Thursday, giving Ark Invest a chance to add on a dip.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innovative treatment optio...

Tempus AI, Inc. ( TEM ) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division Okay. Welcome back, everyone, to the 2025 Stifel Healthcar...

Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid performance in both Genomics and Data/Services segments, with high visibility into future growth. The recent stock pullback, driven by high expectations, presents an attractive entry point for long-...

Tempus AI remains a buy as its data set, testing volumes, and financial results continue to show robust growth. TEM's Genomics segment drives strong revenue growth, with oncology and hereditary testing volumes rising significantly year-over-year. Gross margin expansion, narrowing losses, and a solid cash position highlight TEM's improving profitability and financial health.

Tempus AI is building a strong moat in healthcare AI with vast clinical/genomic datasets and robust infrastructure, driving high-growth potential. TEM achieved its first positive adjusted EBITDA in Q3, signaling improved operational leverage, though GAAP EBITDA remains negative due to adjustments. Despite rapid revenue growth and expanding total addressable market, TEM's high market cap and ong...

Cathie Wood added to her stakes in Archer Aviation, DoorDash, and Tempus AI on Thursday. Archer Aviation is trading lower this year as it ramps up its fleet for high-end short-range air travel.